Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AOC 1020

X
Drug Profile

AOC 1020

Alternative Names: AOC-1020; Del-brax

Latest Information Update: 18 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Avidity Biosciences
  • Class Drug conjugates; Immunoconjugates; Monoclonal antibodies; Oligonucleotides; Small interfering RNA
  • Mechanism of Action DUX4L1 protein expression inhibitors; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Facioscapulohumeral muscular dystrophy
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Facioscapulohumeral muscular dystrophy

Most Recent Events

  • 12 Jun 2024 Efficacy, adverse events and pharmacodynamics data from a phase I/II FORTITUDE trial in Facioscapulohumeral muscular dystrophy released by Avidity
  • 31 Dec 2023 Avidity Biosciences has twelve patents pending for "AOC 1020 and other FSHD AOC composition of matter, formulations containing AOC 1020 and other the FSHD AOC, methods of manufacturing, and methods of treating diseases, using our FSHD AOC" in foreign jurisdictions
  • 31 Dec 2023 Avidity Biosciences has two patent protection for "AOC 1020 and other FSHD AOC composition of matter, formulations containing AOC 1020 and other the FSHD AOC, methods of manufacturing, and methods of treating diseases, using our FSHD AOC" in the US
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top